Profiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world

Authors :: J. Sugisaka
K. Suzuki
Atsushi Nakamura
Y. Toi
Y. Honda
H. Shimizu
K. Tsurumi
Yuichiro Kimura
Y. Kawashima
M. Aso
S. Yamanda
S. Kawana
Y. Domeki
H. Ono
K. Terayama
Ryoko Saito
T. Aiba
Shunichi Sugawara
Source :: Annals of Oncology. 29:ix166
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
Pembrolizumab
medicine.disease
Immune system
Internal medicine
medicine
Non small cell
Nivolumab
Lung cancer
business
Adverse effect

Full Text Access

Tools